120例脑膜瘤病理表型与肿瘤分级及预后的相关性研究

发布时间：2019-01-05 08:48

【摘要】：目的:探讨脑膜瘤组织病理表型与其WHO分级及预后的相关性。方法:采用免疫组化检测120例脑膜瘤病理标本中Vimentin、EMA、S-100、GFAP、Ki67、P53的表达,分析以上分子与脑膜瘤WHO分级、术后复发的相关性。结果:(1)120例脑膜瘤中Vimentin均为阳性表达,EMA平均表达阳性率为90%,Vimentin和EMA表达在3组WHO分级脑膜瘤的组织中差异无统计学意义。(2)S-100平均表达阳性率为23%,在3组WHO分级的脑膜瘤中差异无统计学意义;GFAP平均表达阳性率为4%,在WHOⅡ级脑膜瘤中表达明显高于WHOⅠ级与WHOⅢ级。(3)Ki67和P53的平均阳性表达率为46%和32%,两者均随着脑膜瘤WHO级别升高而表达增高。(4)Ki67的表达与脑膜瘤的复发有相关性。结论:Vimentin和EMA的组织表达阳性可作为脑膜瘤的分子诊断特征;Ki67和P53与脑膜瘤恶性程度密切相关,可以作为良恶性鉴别的分子标志物;Ki67可作为脑膜瘤复发的预后指标之一。
[Abstract]:Objective: to investigate the correlation between pathological phenotype and WHO grade and prognosis of meningioma. Methods: immunohistochemical method was used to detect the expression of Vimentin,EMA,S-100,GFAP,Ki67,P53 in 120 cases of meningioma. The correlation between the above molecules and the WHO grade of meningioma and recurrence after operation was analyzed. Results: (1) the expression of Vimentin was positive in 120 cases of meningioma, and the average positive rate of EMA was 90%. There was no significant difference between the expression of Vimentin and EMA in the three groups of patients with WHO grade meningioma. (2) the average positive rate of S-100 expression was 23%. There was no significant difference in WHO grade meningiomas among the three groups. The average positive rate of GFAP expression in WHO 鈪，

本文编号：2401539